Status:
RECRUITING
Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Conditions:
Epilepsies, Partial
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
To evaluate the long-term safety and tolerability of cenobamate in Japanese epilepsy patients with partial seizures
Eligibility Criteria
Inclusion
- Subjects completed Study YKP3089C035 by SK Life Science.
Exclusion
- Subjects that have previously discontinued for any reason from the Core study (YKP3089C035).
- Any significant changes to the medical history of the subject that in the opinion of the investigator, could affect the safety of the subject.
Key Trial Info
Start Date :
November 4 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06590896
Start Date
November 4 2022
End Date
January 31 2027
Last Update
June 3 2025
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
Ehime University Hospital
Ehime, Japan
2
Department of Neurology and Stroke Center, Southern Tohoku Clinic.
Fukushima, Japan
3
Hiroshima University Hospital
Hiroshima, Japan
4
NHO Kure Medical Center and Chugoku Cancer Center
Hiroshima, Japan